Reglagene, Inc., a pioneering therapeutics company at the forefront of developing breakthrough therapies for brain diseases utilizing small molecule medicines that cross the blood-brain barrier to treat high grade gliomas and other cancers, announced that it has closed its non-brokered private placement of convertible preferred stock.
The offering, which was oversubscribed, resulted in aggregate gross proceeds to the company of $5.4 million, which included principal and interest from convertible debt instruments issued in June 2021 that were automatically converted.
The private placement included participation from management, and from accredited investors including Desert Angels, the Cancer Fund, Tech Coast Angels, Angel Star Ventures, and Viva BioInnovator.
Read more here
